India to Join PIC/S to Safeguard Drug Exports
India is considering joining the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme to safeguard its drug exports.
Singapore: India is mulling over joining a global forum that currently has 43 drug importing countries to ensure safety of drug exports. The forum, officially titled ‘Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme' (PIC/S) has the US and the European Union among its key members.
As per the agreement of this forum, drug regulators of member countries ensure compliance with standards rather than individual manufacturers. The looming fear of India's drug exports suffering in the medium to long term is the reason the country is considering this. "It is going to impact our export growth as more and more countries are now looking for PIC/S compliance. India should join the league at the earliest," said Mr PV Appaji, director general, Pharmaceuticals Export Promotion Council (Pharmaexcil), India.
Further, the country's Commerce Ministry recently initiated a discussion with officials of the Drugs Controller General of India (DCGI) and the health ministry to examine the likely impact of joining the forum.
"As there is the requirement that the whole pharma industry, including non-exporters, be compliant with the standards, the issue needs to studied more carefully," Mr Sudhanshu Pandey, joint secretary, ministry of commerce, opined.
India currently has the highest number of US FDA-approved manufacturing facilities in the world, apart from the US. This is the main reason the country's pharma industry fears losing drug exports to other emerging generic producing nations. India's pharma industry exports grew to $14.5 billion during 2012–2013, up from $13.2 billion the previous year.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance